• Aumolertinib Plus Radiation in EGFR-Mutant NSCLC Brain Metas

  2026-06-29

  This study demonstrates that combining the EGFR inhibitor aumolertinib with ionizing radiation enhances anti-tumor efficacy in EGFR-mutant NSCLC brain metastases. The findings suggest a promising therapeutic approach for overcoming resistance and improving outcomes in this challenging patient population.

• L-NMMA Acetate: Mechanistic Insights for NOS Pathway Researc

  2026-06-29

  Explore the advanced mechanistic roles of L-NMMA acetate in nitric oxide pathway modulation, focusing on its impact in osteogenic and inflammation research. This article offers a unique, evidence-driven perspective for biochemical and pharmacological scientists.

• Atorvastatin: HMG-CoA Reductase Inhibitor in Advanced Resear

  2026-06-28

  Atorvastatin’s dual role as a cholesterol biosynthesis inhibitor and a potent modulator of ferroptosis is redefining experimental strategies in vascular, metabolic, and oncology research. This guide delivers actionable protocols, troubleshooting insights, and a translation of the latest reference findings for lab teams leveraging APExBIO’s Atorvastatin.

• Dissecting Drug Responses: New In Vitro Metrics for Cancer R

  2026-06-27

  Schwartz's dissertation introduces a rigorous distinction between relative and fractional viability in in vitro cancer drug testing, revealing that most antitumor agents exert nuanced, temporally distinct effects on proliferation and cell death. This framework clarifies interpretation of viability data and supports more precise evaluation of candidate compounds in cancer biology.

• Energy Deficiency, ATG4B, and Impaired DNA Repair in AML Pro

  2026-06-26

  This study uncovers how energy deficiency provokes nuclear translocation of ATG4B, which impairs PRMT1-mediated DNA repair in acute myeloid leukemia (AML). The findings provide mechanistic insight into the metabolic control of genomic stability, highlighting potential intervention points for AML progression.

• GKT137831: Dual NADPH Oxidase Nox1/Nox4 Inhibitor for Redox

  2026-06-26

  GKT137831 enables high-fidelity inhibition of reactive oxygen species production in cell and animal models, bridging redox biology with translational disease research. Its validated dual Nox1/Nox4 inhibition unlocks robust workflows for vascular, fibrotic, and metabolic studies—while recent advances connect its use to membrane lipid remodeling and ferroptosis modulation.

• Actinomycin D in Epigenetic RNA Research: Mechanistic and Tr

  2026-06-25

  Explore the cutting-edge role of Actinomycin D in apoptosis induction and RNA methylation studies. This article uniquely bridges DNA damage response mechanisms with epigenetic insights, offering advanced guidance for cancer research and transcriptional stress modeling.

• Disodium Bicinchoninate in Endothelial Dysfunction Research

  2026-06-25

  This thought-leadership article explores the role of disodium bicinchoninate (sodium [2,2'-biquinoline]-4,4'-dicarboxylate) as a water-soluble chelating agent in translational research on oxidative endothelial dysfunction. Leveraging mechanistic insights from recent literature, it provides protocol guidance, competitive positioning, and strategic recommendations for researchers investigating autophagy and inflammation in vascular biology.

• SAR131675 VEGFR-3 Inhibitor: Unlocking Lymphangiogenesis Res

  2026-06-24

  SAR131675, a selective VEGFR-3 inhibitor, is redefining research on lymphangiogenesis, angiogenesis, and fibrotic disease by offering exceptional specificity and robust in vivo efficacy. This article bridges advanced experimental workflows, troubleshooting, and translational findings—empowering scientists to strategically deploy SAR131675 in preclinical models of tumor growth and metabolic liver disease.

• RSL3 Glutathione Peroxidase 4 Inhibitor: Workflows & Innovat

  2026-06-23

  RSL3, a potent glutathione peroxidase 4 inhibitor, has revolutionized the study of ferroptosis in cancer and aging research by enabling precise, reproducible induction of iron-dependent cell death. Its unique selectivity and the wealth of supporting evidence make it the tool of choice for dissecting oxidative stress and redox vulnerabilities in diverse experimental settings.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Me

  2026-06-23

  Xiao et al. have elucidated a novel pathway wherein tumor-associated macrophages (TAMs) accumulate 25-hydroxycholesterol (25HC), leading to lysosomal AMPK activation and metabolic reprogramming that reinforces their immunosuppressive phenotype. This mechanism highlights CH25H and AMPK as potential immunometabolic checkpoints for modulating tumor immune microenvironments.

• Carfilzomib (PR-171): Protocols and Innovations in Cancer Re

  2026-06-22

  Carfilzomib (PR-171) enables researchers to systematically drive apoptosis, paraptosis, and ferroptosis in cancer models, directly addressing radioresistance. This article translates the latest mechanistic findings into actionable protocols, troubleshooting, and advanced application strategies for proteasome inhibition in translational oncology.

• Mouse Neutrophil Cell Isolation Kit: Precision for Tumor Imm

  2026-06-22

  Unlock ultra-pure neutrophil isolation from mouse tissues in 30 minutes—without activation or need for separation columns. This workflow-centric guide reveals how the APExBIO Mouse Neutrophil Cell Isolation Kit (Negative Selection) empowers advanced immuno-oncology research, translating recent mRNA nanovaccine breakthroughs into practical lab strategies.

• MG-132 in Precision Cell Fate Control: Proteasome Inhibition

  2026-06-21

  Explore how MG-132, a potent proteasome inhibitor peptide aldehyde, enables unprecedented precision in cell fate control for cancer research and advanced apoptosis assays. This article reveals new mechanistic insights and practical strategies that go beyond traditional workflows.

• RCN2 Drives ESCC Metastasis and Chemoresistance via PI3K-Akt

  2026-06-20

  This study uncovers Reticulocalbin 2 (RCN2) as a pivotal driver of metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC). By elucidating a novel mechanism involving UBR5-mediated degradation of PPP2CA and subsequent PI3K-Akt pathway activation, the research provides new targets for overcoming treatment resistance.

682 records 7/46 page Previous Next First page 上5页 678910 下5页 Last page